This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Corporate

Apr. 3, 2019

Audentes Therapeutics appoints Mark A. Meltz as first general counsel

Health care industry veteran Mark A. Meltz was appointed as Audentes Therapeutics' first general counsel.

Audentes Therapeutics appoints Mark A. Meltz as first general counsel
Mark A. Meltz

San Francisco-based biotech company Audentes Therapeutics has announced the appointment of Mark A. Meltz as the company’s first general counsel.

Audentes CEO Matthew R. Patterson said Meltz is an experienced leader “with significant industry and subject matter expertise which will be invaluable as we continue to advance our portfolio of product candidates through clinical and regulatory milestones and build a commercial organization...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up